SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

9 marketing jobs

BeiGene logo
2 days ago

Associate Director, Regional Marketing - Southeast

BeiGene

Alabama, NY (On-site)Full time$156K/yr – $206K/yr
BeiGene logo
2 weeks ago

Senior Manager, Marketing – Brukinsa

BeiGene

USA (Remote)Full time$149K/yr – $194K/yr
BeiGene logo
4 weeks ago

Associate Director, Patient Services Promotions (Patient Marketing Experience Required)

BeiGene

USA (Remote)Full time$145K/yr – $195K/yr
BeiGene logo
2 months ago

Associate Director, US Strategy Marketing

BeiGene

USA (Remote)Full time$156K/yr – $206K/yr
BeiGene logo
2 months ago

Senior Director, US Brukinsa HCP and DTC Marketing

BeiGene

USA (Remote)Full time$225K/yr – $295K/yr
BeiGene logo
3 months ago

Director US Strategy Marketing

BeiGene

USA (Remote)Full time$187K/yr – $247K/yr
BeiGene logo
5 months ago

Associate Director, Regional Marketing

BeiGene

California, MO (Remote)Full time$156K/yr – $206K/yr
BeiGene logo
5 months ago

Summer Internship, BeOne Corporate Brand and Reputation Intern

BeiGene

USA (Remote)Full time
BeiGene logo
6 months ago

Director, US Strategy Marketing

BeiGene

USA (Remote)Full time

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

9 jobs
BeiGene logo

Associate Director, Regional Marketing - Southeast

BeiGene

Alabama, NY (On-site)

$156K/yr - $206K/yrIn-houseFull-timeManager8+ years exp.
2 days ago
BeiGene logo

Senior Manager, Marketing – Brukinsa

BeiGene

USA (Remote)

$149K/yr - $194K/yrIn-houseFull-timeSenior level7+ years exp.
2 weeks ago
BeiGene logo

Associate Director, Patient Services Promotions (Patient Marketing Experience Required)

BeiGene

USA (Remote)

$145K/yr - $195K/yrIn-houseFull-timeManager8+ years exp.
4 weeks ago
BeiGene logo

Associate Director, US Strategy Marketing

BeiGene

USA (Remote)

$156K/yr - $206K/yrIn-houseFull-timeSenior level
2 months ago
BeiGene logo

Senior Director, US Brukinsa HCP and DTC Marketing

BeiGene

USA (Remote)

$225K/yr - $295K/yrIn-houseFull-timeSenior level12+ years exp.
2 months ago
BeiGene logo

Director US Strategy Marketing

BeiGene

USA (Remote)

$187K/yr - $247K/yrIn-houseFull-timeDirector/executive
3 months ago
BeiGene logo

Associate Director, Regional Marketing

BeiGene

California, MO (Remote)

$156K/yr - $206K/yrIn-houseFull-timeSenior level8+ years exp.
5 months ago
BeiGene logo

Summer Internship, BeOne Corporate Brand and Reputation Intern

BeiGene

USA (Remote)

In-houseFull-timeIntern/new grad
5 months ago
BeiGene logo

Director, US Strategy Marketing

BeiGene

USA (Remote)

In-houseFull-timeSenior level
6 months ago
BeiGene logo
BeiGene

Associate Director, Regional Marketing - Southeast

Alabama, NY (On-site)

$156K/yr – $206K/yrManager8+ years expFull time

Posted 2 days ago

  • Job
  • Company
  • Salaries
  • People
  • Funding
  • Audience
  • News
  • Links

Job Description

Responsibilities

  • Contribute as a Regional Marketer on the Customer Enterprise Team supporting Hematology portfolio, including Brukinsa (zanubrutinib) and Beqalzi (sonrotoclax) to ensure advocacy development in core hematology indications.
  • Implement integrated KOL and customer engagement strategies and execution plans in support of Brukinsa in CLL and all current indications, as well as Beqalzi in Relapsed and Refractory MCL
  • Build strong partnerships with external KOL customers and partners and influence commercial strategy with internal partners and stakeholders
  • Demonstrate marketing thought leadership and represent BeOne at key US and ex-US meetings, conferences, and functions as needed
  • Actively participate in developing promotional speaker bureau strategy in support of BeOne’s oncology portfolio and education needs for Brukinsa and Beqalzi in current and future indications.
  • Execute integrated commercial and marketing strategic plans at national/regional scientific meetings with collaborative and aligned purpose
  • Partner with Sales, Medical Affairs, Market Access, and Commercial Operations & Business Analytics teams to ensure alignment of BeOne’s US commercialization strategy; Uncover, prioritize, and communicate market insights, challenges/barriers, and solutions to the organization
  • Develop promotional peer-to-peer content and programing including product theaters and other conference promotional education in alignment with annual congress plan
  • Develop and execute integrated commercial advisory boards to gain insights that will inform brand strategies
  • Evaluate and implement innovative KOL tactics to drive brand objectives and strategies

Requirements

  • 8+ years of pharmaceutical industry marketing or related experience (examples include sales, finance, forecasting, market research, healthcare agency, consulting, etc.)
  • A minimum of 3 years of experience in Hematology Oncology sales and/or marketing
  • Demonstrated ability to establish actionable and meaningful relationships with KOL customers as well as with internal commercial teams, medical affairs, clinical development colleagues
  • Skilled in influencing cross-functional teams, including interfacing with key internal and external stakeholders and with scientific and commercial teams
  • Excellent interpersonal, oral, and written communication skills, including demonstrated ability to synthesize data and prepare / deliver a clear overview of commercial insights, opportunity, and risks
  • Demonstrated strength in the core competencies of communication, strategic agility, achieving results, and teamwork/collaboration
  • Education Required: Bachelor’s degree required. Advanced degree (e.g., MA, MBA, PharmD, PhD) preferred in business, economics, biological, or medical sciences. At least 8+ years of industry experience. Hem/Onc background/experience preferred
  • Travel: 50% or more
  • Computer Skills: Proficient with PC and Microsoft Office Suite. Demonstrated ability to put together compelling presentations using Power Point and ability to manage and refine workflow processes with Excel

Preferred

  • Biotech or pharmaceutical US marketplace launch experience preferred
  • Hem/Onc background/experience preferred

Benefits

  • The Company has a comprehensive benefits package that includes Medical, Dental, Vision, 401(k), FSA/HSA, Life Insurance, Paid Time Off, and Wellness.
BeiGene logo

BeiGene

Effective March 17, 2025, The U.S. subsidiary of BeiGene, Ltd. has changed its name to BeOne Medicines USA, Inc. This change comes ahead of our anticipated global rebranding to BeOne Medicines Ltd. and redomiciliation to Switzerland, pending shareholder approval. The new name reflects our commitment to develop innovative medicines and partner with the global community to help as many patients with cancer as possible. To learn more about BeOne Medicines, please follow our new LinkedIn profile @BeOne Medicines.

Founded in 2010
Cambridge, Massachusetts, USA
2.4K employees (105 in marketing)
beonemedicines.com

Salaries

Posted range

$156K/yr – $206K/yr

Taken straight from the job posting.

See all BeiGene salaries

Marketing Team

Marketing Team Size
95 (4% of company)
Median Career Experience
13 years
Median Tenure
4.4 years
Marketing Roles Posted (Last 30 Days)
4

People

Founders / CEO

Tiantian Xie
Tiantian Xie
WPS lead of China R&D, co-Founder Assistant
At the company for 14 years 1 month

HR / Recruitment

Elly Zhu
Elly Zhu
Associate Director, Talent Acquisition, JAPAC
At the company for 6 years 6 months
Brian Choi, SHRM-CP
Brian Choi, SHRM-CP
Associate Talent Acquisition Manager
At the company for 3 years 2 months

Marketing Leadership

Jason French
Jason French
Sr Director Regional Marketing, US
At the company for 4 years 7 months
Greg Koyama
Greg Koyama
Director of Regional Marketing
At the company for 4 years 2 months
Elly Zhu
Elly Zhu
Associate Director, Talent Acquisition, JAPAC
At the company for 6 years 6 months
Karen Bartosh, PA-C, M-PAS, MS
Karen Bartosh, PA-C, M-PAS, MS
Associate Director, Regional Marketing
At the company for 4 years 3 months

Funding

Total Funding
$6.8B
Last Raise
$2.1B
Post IPO Equity, 6 years ago

Funding History

  • Jul 2020
    Post IPO Equity • $2.1B
  • Oct 2019
    Post IPO Equity • $2.7B
  • Aug 2018
    Post IPO Secondary • $903M

Traffic Signals

Monthly Visitors
39.3K
Monthly Google Ads Budget
$37.5K
Traffic Source Mix
Search
31.8%
Direct
20.2%
Referral
41.7%
Social
5.2%
Paid
1%

Headcount Trend

Current headcount: ~2.4K

Recent News

BeiGene stock falls on Trump EO concerns, RBC sees buying opportunity
Sep 11, 2025 • Investing.com
BeiGene beats revenue expectations but misses on earnings in second quarter
Aug 6, 2025 • Investing.com
Lymphoma Treatment Market to Surpass USD 14.66 Billion by 2032, Fueled by Immunotherapy Advancements and Emerging Market Expansion - SNS Insider
Jul 18, 2025 • SNS Insider pvt ltd
Waldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements | DelveInsight
Jul 14, 2025 • GlobeNewswire News Room
Regulatory actions for July 11, 2025
Jul 11, 2025 • BioWorld Financial Watch
PD-1 and PD-L1 Inhibitors Market Report 2025-2034 | Expanding Treatment Options to Impact Market Value, Rising Adoption of Immunotherapies and Regulatory Approvals to Drive Growth
Jul 10, 2025 • GlobeNewswire News Room
Dubai Science Park unites industry leaders to highlight the power of strategic communication in nurturing science and innovation
Jul 8, 2025 • prnewswire.co.uk
BTK inhibitors for autoimmune conditions market
Jul 5, 2025 • PharmiWeb
The Neutralizing Antibody Report 2025 – For Strategy Officers and Market Intelligence Teams
Jul 1, 2025 • EIN Presswire
Bispecific T-cell Engagers (BiTEs) market
Jun 25, 2025 • PharmiWeb
Stocks to Watch today: Union Bank, Hindalco, Vi, JB Chemicals, TaMo, Rites
Jun 25, 2025 • Business Standard India
Waldenstrom Macroglobulinemia: Innovation Heats Up as Next-Gen Therapies Challenge the BTK Standard | CI Insights
Jun 23, 2025 • EIN Presswire
BeiGene Executives Cash In: Massive Stock Sales Unveiled!
Jun 18, 2025 • TipRanks
In-Depth: Behind the Overseas Surge of China’s Innovative Drugs (AI Translation) 【周刊提前读】深度:中国创新药出海爆发背后
Jun 15, 2025 • caixinglobal.com
CSPC Pharma Pursues Licensing Deals After Lackluster Earnings
Jun 12, 2025 • Benzinga.com
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
Jun 11, 2025 • Switzerland Global Enterprise (S-GE)
Glenmark Pharmaceuticals poised to launch Zanubrutinib in India
Jun 9, 2025 • Hindu Business Line
Glenmark to launch DCGI-approved cancer drug in India
Jun 9, 2025 • IndiaTimes
ZhiKe | Are medical funds about to recoup their losses?
May 29, 2025 • 36kr.com
Will Trump's Drug Order Put The Brakes On China's Overseas Pharma Drive?
May 28, 2025 • Benzinga.com
Immuno-Oncology Stars Keytruda, Opdivo Likely To Come Into IRA Crosshairs
May 28, 2025 • BioSpace
BeiGene rebrands, shifts global base to Switzerland
May 27, 2025 • NJBIZ
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer
May 27, 2025 • Business Wire
BeiGene gets EU backing for neck and head cancer treatment
May 27, 2025 • Seeking Alpha
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer
May 27, 2025 • BioSpace
BeiGene's Tevimbra Gets Positive Opinion from Committee for Medicinal Products for Human Use
May 27, 2025 • Morningstar.com
BeiGene's Tevimbra Gets Positive Opinion from Committee for Medicinal Products for Human Use
May 27, 2025 • MarketScreener
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
May 23, 2025 • BioSpace
BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors
May 22, 2025 • BioSpace
Manhattan Associates Unveils Agentic AI Innovation at Momentum 2025
May 22, 2025 • AETOSWire
BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors
May 22, 2025 • AETOSWire
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
May 22, 2025 • MarketScreener
BeiGene's head-to-head test advances | ApexOnco - Clinical Trials news and analysis
May 19, 2025 • Oncology Pipeline
Hillhouse Cashes In on BeiGene Rally; Backs Hengrui Pharma IPO
May 16, 2025 • MarketScreener
Shareholders Would Not Be Objecting To BeiGene, Ltd.'s (NASDAQ:ONC) CEO Compensation And Here's Why
May 15, 2025 • simplywall.st
Innovative Treatments Boost Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Global Market to $13.45 billion By 2029
May 15, 2025 • EIN Presswire
BeiGene remains bold with sonrotoclax | ApexOnco - Clinical Trials news and analysis
May 14, 2025 • Oncology Pipeline
GSK, iTeos Abandon TIGIT Therapy, Adding to Long List of Recent Class Failures
May 14, 2025 • BioSpace
Beigene Agreed 133 Mln New Shares Shall Be Allotted And Issued To Unit
May 14, 2025 • Reuters
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation
May 14, 2025 • Business Wire
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation
May 14, 2025 • BioSpace
BeiGene to Present at the RBC Capital Markets Global Healthcare Conference
May 13, 2025 • BioSpace
BeiGene to Present at the RBC Capital Markets Global Healthcare Conference
May 13, 2025 • Morningstar.com
The Liver Cancer Market 2025: Rising Alcohol Consumption Driving Market Growth Due To Increasing Health Risks
May 13, 2025 • EIN Presswire
Big Chinese pharma firms can withstand Trump’s policies with cost advantages: analysts
May 13, 2025 • South China Morning Post
Earnings Beat: BeiGene, Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
May 10, 2025 • Yahoo Finance
ONC: BeiGene Maintains Rating, Slight Price Target Adjustment | ONC Stock News
May 8, 2025 • GuruFocus
BeiGene Releases Q1 2025 Financial Report
May 8, 2025 • MSN
BeiGene Ltd (ONC) Q1 2025 Earnings Call Highlights: Achieving Profitability and Expanding ...
May 8, 2025 • Yahoo
ONC: BeiGene's Price Target Raised by Guggenheim Analyst | ONC Stock News
May 8, 2025 • GuruFocus
EC approval for BeiGene’s Tevimbra in ES-SCLC
May 8, 2025 • The Pharma Letter
BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit (NASDAQ:ONC)
May 8, 2025 • Seeking Alpha
Market Momentum: BeiGene Ltd. ADR (ONC) Registers a -3.93 Decrease, Closing at 232.25
May 8, 2025 • DWinneX
Beyond the Balance Sheet: What SWOT Reveals About BeiGene Ltd (O
May 8, 2025 • GuruFocus
BeiGene Reports Strong Q1 2025 Growth and Profitability
May 8, 2025 • TipRanks
BeiGene’s Earnings Call: Record Growth & Strategic Advances
May 8, 2025 • TipRanks
Chinese Drugmaker BeiGene Has First Quarterly Profit After Global Sales Surge
May 8, 2025 • yicaiglobal.com
Anti-CD279 (PD-1) Antibody Pipeline Insight Report 2025 Featuring Analysis of 40+ Companies & Drugs Including IBI308 (Innovent Biologics) and Tislelizumab (BeiGene)
May 8, 2025 • Research and Markets
ALX Oncology won’t seek approval for CD47 drug in gastric cancer; Korro Bio’s layoffs
May 8, 2025 • Endpoints News
BeiGene Turns to Q1 Profit
May 8, 2025 • MarketScreener
WuXi AppTec’s Chairman Tops Pay Rankings Among Chinese Mainland-Listed Firms
May 8, 2025 • yicaiglobal.com
BeiGene’s Strong Market Position and Growth Potential Affirmed by Buy Rating
May 7, 2025 • TipRanks
BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne
May 7, 2025 • insights.citeline.com
BeiGene targets $4.9B-$5.3B revenue for 2025 with strong BRUKINSA and pipeline growth
May 7, 2025 • MSN
BeiGene reports Q1 GAAP EPS 1c, consensus (74c)
May 7, 2025 • TipRanks
Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat
May 7, 2025 • Benzinga
BeiGene posts 46% 1st-qtr sales growth, bit misses consensus
May 7, 2025 • The Pharma Letter
Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics
May 7, 2025 • Yahoo Finance
BeiGene (BEIGF) Reports Mixed Q1 Results and Maintains 2025 Guidance
May 7, 2025 • GuruFocus
BeiGene Releases Q1 2025 Financial Report
May 7, 2025 • TipRanks
BeiGene Reports Q1 2025 Financial Results and Business Updates
May 7, 2025 • TipRanks
BeiGene ADS earnings beat by $1.65, revenue fell short of estimates
May 7, 2025 • Investing.com
BeiGene shares tumble over 5% as Q1 revenue misses estimates By Investing.com
May 7, 2025 • Investing.com Nigeria
BeiGene Ltd (ONC) Reports Q1 2025 Earnings: EPS of $0.01, Revenue Surpasses Estimates at $1.1 Billion
May 7, 2025 • GuruFocus
BeiGene Announces First Quarter 2025 Financial Results and Business Updates | ONC Stock News
May 7, 2025 • GuruFocus
BeiGene Announces First Quarter 2025 Financial Results and Business Updates
May 7, 2025 • TradingView
BeiGene, Ltd. SEC 10-Q Report
May 7, 2025 • TradingView
BeiGene shares tumble over 5% as Q1 revenue misses estimates
May 7, 2025 • Investing.com
BeiGene Announces First Quarter 2025 Financial Results and Business Updates
May 7, 2025 • Yahoo Finance
BeiGene Announces First Quarter 2025 Financial Results and Business Updates
May 7, 2025 • Bluefield Daily Telegraph
Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics
May 7, 2025 • Nasdaq
BeiGene Announces First Quarter 2025 Financial Results and Business Updates
May 7, 2025 • BioSpace
BeiGene Announces First Quarter 2025 Financial Results and Business Updates
May 7, 2025 • Business Wire India
BRIEF-BeiGene Posts Q1 Net Income USD 1.3 Million
May 7, 2025 • Reuters
BeiGene Announces First Quarter 2025 Financial Results and Business Updates
May 7, 2025 • Business Wire
Leerink Partnrs Has Pessimistic View of Beigene Q1 Earnings
May 6, 2025 • MarketBeat
BeiGene Wins Patent Challenge Against Pharmacyclics
May 4, 2025 • MSN
Royal Bank of Canada Reiterates "Outperform" Rating for Beigene (NASDAQ:ONC)
May 3, 2025 • MarketBeat
BeiGene Announces Regulatory Filing for ADS Registration
May 2, 2025 • TipRanks
Leerink Partnrs Forecasts Beigene’s Q1 Earnings (NASDAQ:ONC)
May 2, 2025 • Defense World
This Soaring Stock Just Delivered More Good News. Time to Buy?
May 2, 2025 • The Motley Fool
BeiGene scores a win from US Patent Office in spat over Brukinsa
Apr 30, 2025 • Endpoints News
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene
Apr 30, 2025 • Business Wire India
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene
Apr 30, 2025 • UAE Business Review
BeiGene wins US patent dispute over cancer drug
Apr 29, 2025 • Investing.com
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene
Apr 29, 2025 • Business Wire
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene
Apr 29, 2025 • MarketScreener
Is BeiGene (NASDAQ:ONC) Weighed On By Its Debt Load?
Apr 23, 2025 • simplywall.st
BeiGene to Announce First Quarter 2025 Financial Results on May 7
Apr 17, 2025 • Business Wire
nference and BeiGene Collaborate to Drive New B-Cell Cancer Research
Apr 17, 2025 • PR Newswire

Links

beonemedicines.comLinkedInX (Twitter)Crunchbase